Leukemia, Myelocytic, Acute
Blood cancer biotech Vor Bio ends clinical work, lays off 95% of staff
Hematologic Neoplasms, Leukemia, Myelocytic, Acute, Reflex, Vestibulo-Ocular, gene therapy, 95%
Caribou cuts 32% of staff, further purges pipeline to focus on 2 oncology CAR-T prospects
Reindeer, CAR-T, Staff, Neoplasms, Cell Therapy, Allogeneic CRISPR-edited Anti-CD19 CAR-T Cells CB-010, Clustered Regularly Interspaced Short Palindromic Repeats, Leukemia, Myelocytic, Acute, United States Food and Drug Administration, 32%
Orca’s cell therapy trounces traditional care in blood cancer phase 3, swimming into space’s ‘holy grail’
allogeneic hematopoietic stem cell transplant with purging, Leukemia, Myelocytic, Acute, Acute lymphocytic leukemia
Kura Oncology and Kyowa Kirin Report Positive Phase 2 Results for Ziftomenib in AML, Prepare for FDA Submission
Ziftomenib, AML, NPM1-mutant, Phase 2 trial, KOMET-001, FDA submission, Kura Oncology, Kyowa Kirin
Kura Oncology’s Ziftomenib Achieves Phase 2 Success in AML, Paving Way for Dual-Track Phase 3 Program
Ziftomenib, Acute Myeloid Leukemia (AML), NPM1 mutation, KMT2A rearrangement, Phase 3 trials, KOMET-001, KOMET-017, Menin inhibitor, Breakthrough Therapy Designation
Syndax’s Revumenib Shows Promising Results in Acute Leukemia Trials, Paving Way for FDA Approval
Revumenib, Acute Leukemia, AUGMENT-101, SAVE Trial, BEAT AML, Syndax Pharmaceuticals, FDA Approval
Syros Discontinues Mid-Stage Tamibarotene Program in Frontline Acute Myeloid Leukemia (AML)
Syros Pharmaceuticals, Tamibarotene, Acute Myeloid Leukemia (AML), Clinical Trial, SELECT-AML-1, Venetoclax, Azacitidine, RARα Agonist, Futility Analysis
Actinium to Pursue Additional Clinical Trial for AML Radioactive Drug Following FDA Request
Actinium Pharmaceuticals, AML, radioactive drug, FDA, clinical trial, Iomab-B, SIERRA trial